2026-01-15 - Analysis Report
**Company Overview**: Information about this company is not provided.
 
#### Return Rate Comparison
- **Company Stock**: Cumulative return = 148.48%
- **Comparison Stock (S&P 500, VOO)**: Cumulative return = 83.20%
- **Divergence**: Current = 65.30, Relative Divergence = 100.00%

#### Analysis
- The company stock has a significantly higher cumulative return compared to the S&P 500 index, indicating a strong performance of the stock.
- However, the divergence is at its maximum, which might imply a significant over-performance compared to the market.

#### Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2019-2021  | 15.0%| 12.0%| -29.0%| 0.3  | 0.0B  |
| 2020-2022  | -14.0%| 14.1%| -13.0%| 0.3  | 0.0B  |
| 2021-2023  | -23.0%| 14.1%| -24.0%| 0.2  | 0.0B  |
| 2022-2024  | -8.0% | 18.0%| -30.0%| 0.3  | 0.0B  |
| 2023-2025  | 118.0%| 18.0%| 55.0% | 0.2  | 0.0B  |

#### Recent Stock Price Fluctuations
- **Close**: $45,625.00
- **Last-market**: $46,435.00 (with a 1.78% increase)
- **5-day SMA**: $44,773.00
- **20-day SMA**: $40,241.00
- **60-day SMA**: $37,035.58

#### Analysis of Indicators
- **RSI**: 96.78 (very high)
- **PPO**: 1.07 (very high)
- **Market Risk Indicator (MRI)**: 0.70 (medium investment recommended)
- **Expected Return (%)**: -6.20% (compared to S&P 500)
- **Recent (20 days) relative divergence change**: 0.00 (flat)

#### News & Significant Events
- **2026-01-15**: Raymond James Adjusts Price Target on Amazon.com to $260 From $275, Maintains Outperform Rating (MT Newswires)
- **2026-01-15**: New study finds stroke associated with poor glycemic control in diabetics (Clinical Trials Arena)
- **2026-01-15**: Energy Fuels, Up 2.8% In US Premarket, Says U.S. Rare Earth Processing Expansion "Boasts" Low CAPEX, "Significant" Annual EBITDA and Low Cost NdPr Production (MT Newswires)
- **2026-01-15**: Five Below price target raised to $158 from $132 at BofA (TipRanks)
- **2026-01-15**: Here Are My Top 3 Fintech Stocks to Buy Now (Motley Fool)
- **2026-01-15**: BD Receives FDA 510(k) Clearance for EnCor EnCompassâ„¢ Breast Biopsy and Tissue Removal System (PR Newswire)

#### Analyst Opinions
```text
Analyst Consensus:
```

#### Comprehensive Analysis (Summary of previous items)
- The company stock has a significantly higher cumulative return and strong performance, but high divergence.
- The stock's RSI and PPO indices are very high.
- The MRI suggests a medium risk investment.
- The expected return compared to S&P 500 is negative, implying a potential long-term investment risk.
- Recent news highlights various events, including price target adjustments and FDA clearances, but no clear influence on the company stock.
- Analyst opinions are not provided.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.